Advances in diabetes intervention: Targeting hormonal regulation, hIAPP, glucose transport, and key enzymatic pathways

Mulia Safrida Sari, Lilla Puji Lestari, Meri M. Imun, Cut Sriyanti, Nurlaili Ramli

Abstract


Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion or action. This condition remains a leading cause of global morbidity and mortality and is closely associated with various metabolic complications and cancer risk. This study aimed to identify potential molecular targets and hormonal regulatory mechanisms involved in diabetes management. A systematic review was conducted by searching indexed scientific articles in databases such as ScienceDirect and Google Scholar using the keywords “diabetes,” “molecular targets,” “insulin sensitivity,” and “hormonal regulation.” The analysis identified six major molecular mechanisms contributing to improved insulin action and glucose homeostasis, involving targets such as human islet amyloid polypeptide (hIAPP), ?-glucosidase, dipeptidyl peptidase-4 (DPP-4), sodium-glucose co-transporter-2 (SGLT2), glucose transporter type 4 (GLUT4) translocation, RNA-binding proteins (RBPs), and key enzymatic pathways associated with glucose metabolism. The development of therapeutic approaches directed toward these pathways could significantly enhance diabetes control, improve insulin sensitivity, and prevent long-term complications.

Full Text:

PDF

References


Abbas, G., Al Harrasi, A., Hussain, H., Hamaed, A., & Supuran, C. T. (2019). The management of diabetes mellitus-imperative role of natural products against dipeptidyl peptidase-4, ?-glucosidase and sodium-dependent glucose co-transporter 2 (SGLT2). Bioorganic Chemistry, 86, 305–315. Retrieved from https://doi.org/10.1016/j.bioorg.2019.02.009

Borah, A. K., Ahmed, S. A., & Borah, J. C. (2022). Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of diabetic nephropathy. Phytomedicine Plus, 2(2), 100225. Retrieved from https://doi.org/10.1016/j.phyplu.2022.100225

Bryant, N. J., Govers, R., & James, D. E. (2002). Regulated transport of the glucose transporter GLUT4. Nature Reviews Molecular Cell Biology, 3(4), 267–277. Retrieved from https://doi.org/10.1038/nrm782

Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., Sasapu, A., Beebe, A., Patil, N., Musham, C. K., Lohani, G. P., & Mirza, W. (2017). Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Frontiers in Endocrinology, 8. Retrieved from https://doi.org/10.3389/fendo.2017.00006

Chen, X., Wu, J., Li, Z., Han, J., Xia, P., Shen, Y., Ma, J., Liu, X., Zhang, J., & Yu, P. (2022). Advances in the study of RNA-binding proteins in diabetic complications. Molecular Metabolism, 62, 101515. Retrieved from https://doi.org/10.1016/j.molmet.2022.101515

Cooper, M. S., & Stewart, P. M. (2009). 11?-Hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. The Journal of Clinical Endocrinology & Metabolism, 94(12), 4645–4654. Retrieved from https://doi.org/10.1210/jc.2009-1412

Djrolo, F., Paraïso, N. M., Diarra, O., & Makoutode, M. (2014). Diabetes complications and associated factors in type 2 diabetic patients in Cotonou. Journal of Diabetes Mellitus, 4(04), 311. Retrieved from https://doi.org/10.4236/jdm.2014.44043

Fernandez-Ruiz, R., Vieira, E., Garcia-Roves, P. M., & Gomis, R. (2014). Protein tyrosine phosphatase-1B modulates pancreatic ?-cell mass. PLoS ONE, 9(2), e90344. Retrieved from https://doi.org/10.1371/journal.pone.0090344

Garcia, D., & Shaw, R. J. (2017). AMPK: Mechanisms of cellular energy sensing and restoration of metabolic balance. Molecular Cell, 66(6), 789–800. Retrieved from https://doi.org/10.1016/j.molcel.2017.05.032

Gautier, J. F., Monguillon, P., Verier-Mine, O., Valensi, P., Fiquet, B., Dejager, S., & Charbonnel, B. (2016). Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin? Diabetes Research and Clinical Practice, 116, 26–28. Retrieved from https://doi.org/10.1016/j.diabres.2016.04.008

Gjessing, H. J., Jørgensen, U. L., Møller, C. C., Pedersen, J., Grodum, E., & Schousboe, K. (2014). Better glycaemic outcome, low levels of acute severe complications, and high patient satisfaction in routine practice in type 1 diabetes treated with an insulin pump. Journal of Diabetes Mellitus, 04(04), 304–310. Retrieved from https://doi.org/10.4236/jdm.2014.44042

Handorf, A. M., Sollinger, H. W., & Alam, T. (2015). Genetic engineering of surrogate ? cells for treatment of type 1 diabetes mellitus. Journal of Diabetes Mellitus, 05(04), 295–312. Retrieved from https://doi.org/10.4236/jdm.2015.54037

Hocher, B., Reichetzeder, C., & Alter, M. L. (2012). Renal and cardiac effects of DPP4 inhibitors–from preclinical development to clinical research. Kidney and Blood Pressure Research, 36(1), 65–84. Retrieved from https://doi.org/10.1159/000339028

Hunter, R. W., Hughey, C. C., Lantier, L., Sundelin, E. I., Peggie, M., Zeqiraj, E., Sicheri, F., Jessen, N., Wasserman, D. H., & Sakamoto, K. (2018). Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. Nature Medicine, 24(9), 1395–1406. Retrieved from https://doi.org/10.1038/s41591-018-0159-7

International Diabetes Federation. (2000). Diabetes atlas 2000 (1st ed.). International Diabetes Federation. Retrieved from https://diabetesatlas.org/atlas/first-edition/

International Diabetes Federation. (2013). IDF diabetes atlas (6th ed.). International Diabetes Federation. Retrieved from https://diabetesatlas.org/atlas/sixth-edition/

International Diabetes Federation. (2015). IDF diabetes atlas (7th ed.). International Diabetes Federation. Retrieved from https://diabetesatlas.org/atlas/seventh-edition/

International Diabetes Federation. (2019). IDF diabetes atlas (9th ed.). International Diabetes Federation. Retrieved from https://diabetesatlas.org/atlas/ninth-edition/

Kanwal, A., Kanwar, N., Bharati, S., Srivastava, P., Singh, S. P., & Amar, S. (2022). Exploring new drug targets for type 2 diabetes: Success, challenges and opportunities. Biomedicines, 10(2), 331. Retrieved from https://doi.org/10.3390/biomedicines10020331

Kaur, R., Dahiya, L., & Kumar, M. (2017). Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus. European Journal of Medicinal Chemistry, 141, 473–505. Retrieved from https://doi.org/10.1016/j.ejmech.2017.09.029

Keri, K. C., Samji, N. S., & Blumenthal, S. (2018). Diabetic nephropathy: newer therapeutic perspectives. Journal of Community Hospital Internal Medicine Perspectives, 8(4), 200–207. Retrieved from https://doi.org/10.1080/20009666.2018.1500423

Kerru, N., Singh-Pillay, A., Awolade, P., & Singh, P. (2018). Current anti-diabetic agents and their molecular targets: A review. European Journal of Medicinal Chemistry, 152, 436–488. Retrieved from https://doi.org/10.1016/j.ejmech.2018.04.061

Kim, Y., & Park, C. W. (2017). New therapeutic agents in diabetic nephropathy. The Korean Journal of Internal Medicine, 32(1), 11–25. Retrieved from https://doi.org/10.3904/kjim.2016.174

King, G. L., Park, K., & Li, Q. (2016). Selective insulin resistance and the development of cardiovascular diseases in diabetes: The 2015 edwin bierman award lecture. Diabetes, 65(6), 1462–1471. Retrieved from https://doi.org/https://doi.org/10.2337/db16-0152

Kleiner, S., Mepani, R. J., Laznik, D., Ye, L., Jurczak, M. J., Jornayvaz, F. R., Estall, J. L., Chatterjee Bhowmick, D., Shulman, G. I., & Spiegelman, B. M. (2012). Development of insulin resistance in mice lacking PGC-1? in adipose tissues. Proceedings of the National Academy of Sciences, 109(24), 9635–9640. Retrieved from https://doi.org/10.1073/pnas.1207287109

Kobayashi, M., Tsukube, S., Ikeda, Y., & Shuto, Y. (2014). Safety and efficacy of combination therapy with insulin glargine and oral hypoglycaemic agents including DPP-4 inhibitors in Japanese T2DM patients: ALOHA 2 study, a post-marketing surveillance for Lantus®. Journal of Diabetes Mellitus, 4(04), 273–289. Retrieved from https://doi.org/10.4236/jdm.2014.44039

Lee, D., Pagire, H. S., Pagire, S. H., Bae, E. J., Dighe, M., Kim, M., Lee, K. M., Jang, Y. K., Jaladi, A. K., Jung, K.-Y., Yoo, E. K., Gim, H. E., Lee, S., Choi, W.-I., Chi, Y.-I., Song, J. S., Bae, M. A., Jeon, Y. H., Lee, G.-H., … Ahn, J. H. (2019). Discovery of novel pyruvate dehydrogenase kinase 4 inhibitors for potential oral treatment of metabolic diseases. Journal of Medicinal Chemistry, 62(2), 575–588. Retrieved from https://doi.org/10.1021/acs.jmedchem.8b01168

Lee, I.-K. (2014). The role of pyruvate dehydrogenase kinase in diabetes and obesity. Diabetes & Metabolism Journal, 38(3), 181–186. Retrieved from https://doi.org/10.4093/dmj.2014.38.3.181

Lee, J. O., Lee, S. K., Kim, J. H., Kim, N., You, G. Y., Moon, J. W., Kim, S. J., Park, S. H., & Kim, H. S. (2012). Metformin regulates glucose transporter 4 (GLUT4) translocation through AMP-activated protein kinase (AMPK)-mediated Cbl/CAP signaling in 3T3-L1 preadipocyte cells. Journal of Biological Chemistry, 287(53), 44121–44129. Retrieved from https://doi.org/https://doi.org/10.1074/jbc.M112.361386

Liu, G.-M., & Zhang, Y.-M. (2018). Targeting FBPase is an emerging novel approach for cancer therapy. Cancer Cell International, 18(1), 36. Retrieved from https://doi.org/10.1186/s12935-018-0533-z

Luo, T., Nocon, A., Fry, J., Sherban, A., Rui, X., Jiang, B., Xu, X. J., Han, J., Yan, Y., & Yang, Q. (2016). AMPK activation by metformin suppresses abnormal extracellular matrix remodeling in adipose tissue and ameliorates insulin resistance in obesity. Diabetes, 65(8), 2295–2310. Retrieved from https://doi.org/10.2337/db15-1122

Mansour, M., Salam, R. F., Rashed, L., & Salam, H. (2014). Role of toll receptors in diabetic nephropathy. Journal of Diabetes Mellitus, 4(01), 26–32. Retrieved from https://doi.org/10.4236/jdm.2014.41005

McCarty, M. F., & DiNicolantonio, J. J. (2015). Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart, 2(1), e000205. Retrieved from https://doi.org/10.1136/openhrt-2014-000205

Méndez, M., Matter, H., Defossa, E., Kurz, M., Lebreton, S., Li, Z., Lohmann, M., Löhn, M., Mors, H., Podeschwa, M., Rackelmann, N., Riedel, J., Safar, P., Thorpe, D. S., Schäfer, M., Weitz, D., & Breitschopf, K. (2020). Design, synthesis, and pharmacological evaluation of potent positive allosteric modulators of the glucagon-like peptide-1 receptor (GLP-1R). Journal of Medicinal Chemistry, 63(5), 2292–2307. Retrieved from https://doi.org/10.1021/acs.jmedchem.9b01071

Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., .. & Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. Retrieved from https://doi.org/10.1016/j.molmet.2019.09.010

Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 20(S1), 5–21. Retrieved from https://doi.org/10.1111/dom.13129

Nguyen, N. D. T., & Le, L. T. (2012). Targeted proteins for diabetes drug design. Advances in Natural Sciences: Nanoscience and Nanotechnology, 3(1), 013001. Retrieved from https://doi.org/10.1088/2043-6262/3/1/013001

Ni, L., Yuan, C., Chen, G., Zhang, C., & Wu, X. (2020). SGLT2i: Beyond the glucose-lowering effect. Cardiovascular Diabetology, 19(1), 98. Retrieved from https://doi.org/10.1186/s12933-020-01071-y

Ozougwu, J. C., Obimba, K. C., Belonwu, C. D., & Unakalamba, C. B. (2013). The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. Journal of Physiology and Pathophysiology, 4(4), 46–57. Retrieved from https://doi.org/10.5897/JPAP2013.0001

Penumathsa, S. V., Thirunavukkarasu, M., Zhan, L., Maulik, G., Menon, V. P., Bagchi, D., & Maulik, N. (2008). Resveratrol enhances GLUT?4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. Journal of Cellular and Molecular Medicine, 12(6a), 2350–2361. Retrieved from https://doi.org/10.1111/j.1582-4934.2008.00251.x

Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014). GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology, 155(4), 1280–1290. Retrieved from https://doi.org/10.1210/en.2013-1934

Ramesh, R., AdhishwarKumaran, N., KuzhandaiVelu, V., Reeta, R., SathishBabu, M., & Niranjan, G. (2015). Association between hepato-biliary status and HbA1c in type 2 diabetes mellitus with coronary artery disease (CAD). Journal of Diabetes Mellitus, 5(02), 67–71. Retrieved from https://doi.org/10.4236/jdm.2015.52008

Roham, P. H., Save, S. N., & Sharma, S. (2022). Human islet amyloid polypeptide: A therapeutic target for the management of type 2 diabetes mellitus. Journal of Pharmaceutical Analysis, 12(4), 556–569. Retrieved from https://doi.org/10.1016/j.jpha.2022.04.001

Satoh, T. (2014). Molecular mechanisms for the regulation of insulin-stimulated glucose uptake by small guanosine triphosphatases in skeletal muscle and adipocytes. International Journal of Molecular Sciences, 15(10), 18677–18692. Retrieved from https://doi.org/10.3390/ijms151018677

Schleicher, E. D., & Weigert, C. (2000). Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney International, 58, S13–S18. Retrieved from https://doi.org/10.1046/j.1523-1755.2000.07703.x

Shalan, N., Al-Bazzaz, A., Al-Ani, I., Najem, F., & Al-Masri, M. (2015). Effect of carbon dioxide therapy on diabetic foot ulcer. Journal of Diabetes Mellitus, 05(04), 284–289. Retrieved from https://doi.org/10.4236/jdm.2015.54035

Sharma, P., Singh, S., Thakur, V., Sharma, N., & Grewal, A. S. (2021). Novel and emerging therapeutic drug targets for management of type 2 Diabetes Mellitus. Obesity Medicine, 23, 100329. Retrieved from https://doi.org/10.1016/j.obmed.2021.100329

Shroff, G. (2015a). A scoring system to assess patients with diabetes: Nutech functional score. Journal of Diabetes Mellitus, 5(04), 245–251. Retrieved from https://doi.org/10.4236/jdm.2015.54030

Shroff, G. (2015b). Use of human embryonic stem cells in the treatment of diabetes mellitus: A case series. Journal of Diabetes Mellitus, 05(04), 313–318. Retrieved from https://doi.org/10.4236/jdm.2015.54038

Spangler, J. G., & Kirk, J. (2014). Correlation between diabetes prevalence and subsequent cancer mortality in North Carolina counties. Journal of Diabetes Mellitus, 4(01), 1–5. Retrieved from https://doi.org/10.4236/jdm.2014.41001

Srivastava, R. A. K., Pinkosky, S. L., Filippov, S., Hanselman, J. C., Cramer, C. T., & Newton, R. S. (2012). AMP-activated protein kinase: An emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. Journal of Lipid Research, 53(12), 2490–2514. Retrieved from https://doi.org/10.1194/jlr.R025882

Sumitani, S., Morita, S., Deguchi, R., Hirai, K., Mukai, K., Utsu, Y., Miki, S., Sato, B., Nakamura, H., & Kasayama, S. (2014). Improved ?-cell function rather than increased insulin sensitivity is associated with reduction in hemoglobin A1c in newly diagnosed type 2 diabetic patients treated with metformin. Journal of Diabetes Mellitus, 4(01), 44–49. Retrieved from https://doi.org/10.4236/jdm.2014.41008

Vallon, V. (2015). The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annual Review of Medicine, 66(1), 255–270. Retrieved from https://doi.org/10.1146/annurev-med-051013-110046

Wenz, T., Rossi, S. G., Rotundo, R. L., Spiegelman, B. M., & Moraes, C. T. (2009). Increased muscle PGC-1? expression protects from sarcopenia and metabolic disease during aging. Proceedings of the National Academy of Sciences, 106(48), 20405–20410. Retrieved from https://doi.org/10.1073/pnas.0911570106

Yang, J. (2010). Role of clusters in insulin-regulated GLUT4 trafficking in adipose cells: A new paradigm? International Journal of Biological Sciences, 6(7), 716–718. Retrieved from https://doi.org/10.7150/ijbs.6.716

Yu, L.-F., Qiu, B.-Y., Nan, F.-J., & Li, J. (2010). AMPK activators as novel therapeutics for type 2 diabetes. Current Topics in Medicinal Chemistry, 10(4), 397–410. Retrieved from https://doi.org/10.2174/156802610790980611

Zhou, Q., Yang, X., Xiong, M., Xu, X., Zhen, L., Chen, W., Wang, Y., Shen, J., Zhao, P., & Liu, Q.-H. (2016). Chloroquine increases glucose uptake via enhancing GLUT4 translocation and fusion with the plasma membrane in L6 cells. Cellular Physiology and Biochemistry, 38(5), 2030–2040. Retrieved from https://doi.org/10.1159/000445562

Zhu, X., Zhu, D., Li, X., Li, Y., Jin, X., Hu, T., Zhao, Y., Li, Y., Zhao, G., Ren, S., Zhang, Y., Ding, Y., & Chen, L. (2018). Dorzagliatin (HMS5552), a novel dual?acting glucokinase activator, improves glycaemic control and pancreatic ??cell function in patients with type 2 diabetes: A 28?day treatment study using biomarker?guided patient selection. Diabetes, Obesity and Metabolism, 20(9), 2113–2120. Retrieved from https://doi.org/10.1111/dom.13338




DOI: https://doi.org/10.31932/jpbio.v10i2.4850

Article Metrics

Abstract view : 32 times
PDF - 19 times

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.